Hyperglycosylated hCG Drives Malignancy in Most or All Human Cancers: Tying All Research Together - Pages 14-21

Laurence A. Cole

https://doi.org/10.6000/1927-7229.2018.07.01.3

Published: 28 February 2018

Abstract: Objectives: Two forms of hCG are produced, the hormone hCG binding a luteinizing hormone/hCG joint receptor and the autocrine hyperglycosylated hCG binding a TGF-ß receptor. In pregnancy, hyperglycosylated hCG drives placental cell growth and invasion in implantation of pregnancy. It also blocks apoptosis. Human cancer cells steal the hCG ß-subunit gene and use hyperglycosylated hCG and its ß-subunit to drive malignancy. Here we examine research into hyperglycosylated hCG and its ß-subunit, and show that these molecules drive malignancy in most or possibly all human cancers.

Methods: Mouse monoclonal antibody B152was raised against intact hyperglycosylated hCG, batch C5. The antibody binds hyperglycosylated hCG and its ß-subunit but does not bind the hormone hCG or its subunits. Total hCG was measured using the Siemens Immulite hCG assay, hyperglycosylated hCG and its ß-subunit were measured using the antibody B152 assay.

Results: Eight independent center show that the hCG ß-subunit produced by cancers promotes malignancy, enhances cancer cell growth, cancer cell invasion and blockage of apoptosis in cancers. A study of 42 choriocarcinoma cases shows that percentage hyperglycosylated hCG exactly correlates with weekly doubling rate of cancer. It is concluded that hyperglycosylated hCG drive malignancy in this cancer. In a study with 7 separate cancers it is shown that increasing concentrations of hyperglycosylated hCG enhance all cancers. Increasing concentration of monoclonal antibody B152.

Hyperglycosylated hCG and its ß-subunit drives cancer growth, cancer invasion and blocks apoptosis in cancer cells. Antibody B152 suppressed cancer cell growth creating a non-malignant-like state (no growth, no invasion), with no cancer growth over a starting 70% confluency.

Conclusions: Choriocarcinoma is an example of cancer driven in malignancy by hyperglycosylated hCG, cancer aggression (weekly doubling rate) exactly correlating with percent hyperglycosylated hCG. In examining cancers, antibody B152 suppresses malignancy totally halting cancer growth in 7 of 7 cancer. This confirms that only the antigens, hyperglycosylated hCG and its ß-subunit drives malignancy in cancer cases.

Keywords: hCG, hyperglycosylated hCG, malignancy.

Strength Training as an Adjunct to the Maintenance of Muscle Mass in Patients with Head and Neck Cancer - Pages 22-24
Adilson Domingos dos Reis Filho, Fernando Tadeu Trevisan Frajacomo, Roberto Carlos Vieira Junior, Haracelli Christina Barbosa Alves Leite da Costa, James Wilfred Navalta, Ramires Alsamir Tibana, Jonato Prestes and Fabrício Azevedo Voltarelli

https://doi.org/10.6000/1927-7229.2018.07.02.1

Published: 17 April 2018

Abstract: Head and neck cancer (HNC) is one of the most common types of the disease, particularly among men, and is characterized by a high incidence of death. Among the non-pharmacological factors that help in survival and improving quality of life is physical exercise, especially strength training. The purpose of this short communication was to briefly review the literature and present a training proposal for oncology patients with HNC. Evidence is provided that physical exercise, mainly short-term strength (HIIT [High-Intensity Interval Training]) and aerobic training, contributes to increased expectation and quality of life in cancer survivors. After reviewing the current state of literature, we conclude that strength training, by providing maintenance of muscle mass, improves the autonomy and quality of life of oncology patients with HNC.

Keywords: Cancer, exercise, strength training, health.